Ann Arbor cholesterol drug startup headed toward IPO?
A cholesterol drug startup with dual headquarters in Ann Arbor and France could be headed toward an initial public offering, according to a Bloomberg report.
That comes after Cerenis CEO Jean-Louis Dasseux said in 2011 that "he may consider funding options including an IPO in 2013," the news agency reported.
The startup's most advanced therapy, a drug called CER-001, would treat acute coronary syndrome. Cerenis has several other treatments that would improve the body’s production of HDL cholesterol, which helps the body eliminate harmful lipids and plaque that can cause diseases.
Among the company's investors is Ann Arbor-based EDF Ventures.